查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2085837

免疫檢測市場：按類型、技術、儀器、檢體類型、檢測方法、應用領域、最終用戶和部署模式分類——2026-2032年全球市場預測

Immunoassay Market by Type, Technology, Instruments, Sample Types, Detection Modes, Application Areas, End Users, Deployment Types - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，免疫檢測市場將成長至 499.8 億美元，複合年成長率為 7.36%。

主要市場統計數據
基準年 2025 303.8億美元
預計年份：2026年 326.1億美元
預測年份 2032 499.8億美元
複合年成長率 (%) 7.36%

免疫檢測是現代診斷的核心分析技術，它利用高度特異性的抗原-抗體結合來檢測血液、血清、血漿、唾液、尿液和其他檢體中的生物標記。成熟的免疫檢測法，例如酵素免疫分析法（ELISA）、化學化學冷光免疫檢測、螢光免疫分析、放射免疫分析和側向流動免疫檢測試驗，為感染疾病、腫瘤、心臟病、內分泌、過敏、毒理學、自體免疫疾病、不孕症和治療藥物監測等領域的臨床檢測提供了支持。

這種需求源自於可衡量的醫療保健需求，包括人口老化、慢性病流行、抗生素抗藥性監測、產前篩檢、血液安全以及應對疫情的準備。世界衛生組織（世衛組織）的數據顯示，非傳染性疾病約佔全球死亡人數的74%，這進一步增加了擴充性生物標記檢測的需求。免疫檢測憑藉其可擴展的處理能力、臨床親和性、與自動化系統的兼容性、經濟高效的工作流程以及在集中式和分佈式即時檢查室中快速提供結果的能力，保持著重要的戰略地位。

免疫檢測領域的變革性變化

免疫檢測領域正從獨立的手動工作流程轉向自動化、互聯互通的多參數診斷生態系統。臨床檢查室優先考慮高通量分析儀、標準化試劑平台、品管以及與實驗室資訊系統的整合，以減少變異性、提高可追溯性並支援更快的臨床決策。

人工智慧在免疫檢測中的累積影響

人工智慧（AI）正成為加速免疫檢測開發和應用的重要驅動力。 AI驅動的影像分析提高了側向流動和螢光測量的準確性，而機器學習則透過模擬抗體-抗原相互作用、背景雜訊、交叉反應風險、干擾模式和校準曲線性能來幫助最佳化檢測法。

關於免疫檢測的關鍵區域見解

亞太地區（包括中國、印度、日本、韓國、澳洲和東南亞國家）的免疫檢測市場正經歷著蓬勃發展，這主要得益於大規模的患者群體、不斷完善的診斷基礎設施、日益​​成長的慢性病檢測以及自動化和即時檢測（POC​​）平台的廣泛應用。北美市場則依然高度成熟，這得益於監管創新、醫院網路、參考實驗室、保險報銷機制、公共衛生檢測能力以及自動化免疫檢測平台在感染疾病、內分泌、心臟病、腫瘤和治療監測等領域的廣泛應用。

免疫檢測的主要群體分析

在東南亞國協，免疫檢測的應用正隨著感染疾病監測、孕產婦保健計劃、醫院檢查室現代化以及都市區對私人診斷服務日益成長的需求而不斷擴大。在海灣合作理事會國家，為配合國家醫療衛生轉型議程，各國正增加對先進急診醫院、檢查室自動化、區域衛生安全能力和預防性篩檢的投資。在歐盟，體外醫療設備法規（IVDR）日益強調循證方法，並優先考慮擁有完善的臨床檢驗、可追溯性、品管系統和上市後監測記錄的供應商。

主要國家免疫檢測方法的發展趨勢

在美國，大規模參考實驗室、綜合醫院系統、完善的FDA核准流程以及對腫瘤、心臟病、感染疾病、自體免疫疾病、過敏和內分泌疾病檢測的強勁需求，正在推動免疫檢測的商業化。加拿大在其公共醫療體系內強調品質保證的診斷，而墨西哥和巴西則兼顧了傳染病檢查、慢性病篩檢的需求以及不斷成長的私人實驗室網路。英國、德國、法國、義大利和西班牙仍然是歐洲免疫檢測應用的核心，這得益於完善的臨床指南、實驗室認證、全民或近乎全民的醫療保健體係以及先進的基礎設施。

為免疫檢測行業的領導者提供的實用建議

產業領導者應優先考慮一系列具有明確臨床效用的檢測項目，包括感染疾病檢測、心臟標記檢測、甲狀腺功能檢測、不孕症檢測、腫瘤生物標記檢測、自體免疫疾病檢測、過敏診斷、發炎標記檢測和藥物監測。競爭優勢源自於已驗證的靈敏度、特異性、重複性、批間一致性、校準穩定性、干擾控制以及與分析儀器的無縫整合。

調查方法

本執行摘要是基於對公開權威資料的系統性審查，包括監管指南、臨床實驗室標準、世界衛生組織 (WHO) 資料、同行評審文獻、醫療保健系統報告、公共採購資訊來源以及領先診斷製造商的資訊披露。

結論

免疫檢測將繼續作為診斷領域的基礎性技術，滿足大量的臨床需求，同時不斷適應自動化、多重檢測、即時檢測、數位連接和人工智慧驅動的工作流程支援。其在慢性病管理、感染疾病監測、預防性篩檢、血液安全、治療監測和精準醫療等領域的應用，進一步凸顯了該技術的長期重要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：免疫檢測市場：依類型分類

  • 定性免疫檢測
  • 定量免疫檢測

第8章免疫檢測市場：依技術分類

  • 酵素免疫分析法
  • 酵素結合免疫吸附檢測法
  • 螢光免疫分析
  • 橫向流動化驗
  • 免疫測量
  • 西方墨點法

第9章免疫檢測市場：依設備分類

  • 分析儀器和試劑盒
  • 生物感測器
  • 微流體裝置
  • 微孔盤
  • PCR設備
  • 試劑
    • 抗體
    • 抗原
    • 封閉試劑
    • 緩衝液和標準品
    • 酵素
    • 基材
  • 軟體服務

第10章：免疫檢測市場：依檢體類型分類

  • 血液檢體
  • 唾液檢體
  • 組織檢體
  • 尿液檢體

第11章免疫檢測市場：依檢測模式分類

  • 化學冷光
  • 比色法
  • 螢光檢測法
  • 放射性同位素法

第12章：免疫檢測市場：依應用領域分類

  • 過敏
  • 自體免疫疾病
  • 循環系統
  • 內分泌學
  • 感染疾病
  • 腫瘤學
  • 毒理學
    • 藥物篩檢
    • 環境測試

第13章：免疫檢測市場：依最終用戶分類

  • 受託研究機構
  • 診斷檢查室
  • 醫院和診所
  • 製藥和生物技術公司
  • 研究機構

第14章免疫檢測市場：依導入類型分類

  • 臨床試驗
  • 即時檢測

第15章：免疫檢測市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第16章：免疫檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章免疫檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第19章：公司簡介

  • Abbott Laboratories
  • Agilent Technologies Inc.
  • ANP Technologies, Inc.
  • Autobio Diagnostics Co., Ltd.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • bioMerieux SA
  • Biosurfit SA
  • Boditech Med Inc.
  • Danaher Corporation
  • Diasorin SpA
  • Dynex Technologies, Inc.
  • Epitope Diagnostics Inc.
  • F. Hoffmann-La Roche Ltd.
  • Fapon Biotech Inc.
  • HU Group Holdings Inc.
  • J. Mitra & Co. Pvt. Ltd.
  • Kamiya Biomedical Company
  • Merck KGaA
  • MiCo BioMed, Inc.
  • NanoEntek
  • Nanomix, Inc.
  • OPKO Health, Inc.
  • Promega Corporation
  • QIAGEN NV
  • Quanterix Corporation
  • Randox Laboratories Ltd.
  • Shenzhen Micropoint Biotechnologies Co., Ltd.
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Tosoh Corporation
  • WAK-Chemie Medical GmbH
  • Zoetis Inc.
  • Zybio Inc.
Product Code: MRR-43127F7279BC

The Immunoassay Market is projected to grow by USD 49.98 billion at a CAGR of 7.36% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 30.38 billion
Estimated Year [2026] USD 32.61 billion
Forecast Year [2032] USD 49.98 billion
CAGR (%) 7.36%

Immunoassay is a core analytical technology in modern diagnostics, using highly specific antigen-antibody binding to detect biomarkers in blood, serum, plasma, saliva, urine, and other specimen types. Established formats such as enzyme-linked immunosorbent assay (ELISA), chemiluminescent immunoassay, fluorescence immunoassay, radioimmunoassay, and lateral flow immunoassay support clinical testing across infectious disease, oncology, cardiology, endocrinology, allergy, toxicology, autoimmune disease, fertility, and therapeutic drug monitoring.

Demand is supported by measurable healthcare needs, including aging populations, chronic disease prevalence, antimicrobial resistance surveillance, prenatal screening, blood safety, and pandemic preparedness. The World Health Organization reports that noncommunicable diseases account for about 74% of global deaths, reinforcing the need for scalable biomarker testing. Immunoassay remains strategically important because it combines scalable throughput, clinical familiarity, automation compatibility, cost-efficient workflows, and rapid turnaround for centralized laboratories and decentralized point-of-care testing.

Transformative Shifts in the Immunoassay Landscape

The immunoassay landscape is shifting from standalone, manual workflows toward automated, connected, and multiplexed diagnostic ecosystems. Clinical laboratories are prioritizing high-throughput analyzers, standardized reagent platforms, quality controls, and interfaces with laboratory information systems to reduce variability, improve traceability, and support faster clinical decisions.

At the same time, point-of-care immunoassay adoption is expanding as health systems seek earlier detection outside central labs, especially in emergency departments, primary care, pharmacies, rural clinics, and outbreak settings. Regulatory scrutiny is also increasing, particularly under the EU In Vitro Diagnostic Regulation and FDA oversight of higher-risk diagnostics, making analytical validation, clinical performance evidence, risk management, usability, and post-market surveillance essential competitive differentiators.

Cumulative Impact of Artificial Intelligence on Immunoassay

Artificial intelligence is becoming an operational accelerator for immunoassay development and deployment. AI-enabled image analysis can improve interpretation of lateral flow and fluorescence results, while machine learning supports assay optimization by modeling antibody-antigen interactions, background noise, cross-reactivity risk, interference patterns, and calibration curve performance.

In laboratories, AI contributes to predictive maintenance, workload forecasting, reflex-testing rules, result verification, and anomaly detection in quality control data. Its strongest near-term value is not replacing immunoassay science but improving reproducibility, throughput, and clinical integration when paired with validated datasets, transparent governance, cybersecurity controls, human oversight, and regulatory-grade documentation.

Key Regional Insights for Immunoassay

Asia-Pacific is a dynamic immunoassay region because China, India, Japan, South Korea, Australia, and Southeast Asian economies combine large patient pools with expanding diagnostic infrastructure, rising chronic disease testing, and greater use of automated and point-of-care platforms. North America remains highly mature, supported by regulated innovation, hospital networks, reference laboratories, reimbursement pathways, public health testing capacity, and strong uptake of automated immunoassay platforms for infectious disease, endocrine, cardiac, oncology, and therapeutic monitoring applications.

Europe is shaped by advanced laboratory medicine, national screening programs, accreditation practices, and stricter In Vitro Diagnostic Regulation evidence requirements, which increase the importance of clinical validation and post-market performance monitoring. Latin America is improving immunoassay access through private laboratory chains, public screening initiatives, and infectious disease testing for conditions such as dengue, HIV, hepatitis, and respiratory infections. The Middle East is investing in hospital modernization, preventive screening, specialty diagnostics, and laboratory automation, while Africa's opportunity is strongly linked to scalable point-of-care immunoassays for HIV, malaria, hepatitis, pregnancy, tuberculosis screening support, and outbreak response, where decentralized testing can close access gaps in underserved areas.

Key Group Insights for Immunoassay

ASEAN countries are expanding immunoassay use through infectious disease surveillance, maternal health programs, hospital laboratory upgrades, and rising private diagnostics demand across urban centers. The GCC is investing in high-acuity hospitals, laboratory automation, local health security capacity, and preventive screening aligned with national health transformation agendas. The European Union is increasingly evidence-driven under IVDR, favoring suppliers with robust clinical validation, traceability, quality management systems, and documented post-market surveillance.

BRICS markets offer scale and localization potential, particularly where public procurement, domestic manufacturing policies, technology transfer, and access-oriented pricing influence adoption. G7 markets lead in premium analyzer adoption, companion diagnostics, reimbursement standards, laboratory accreditation, and digital laboratory integration. NATO members' broader emphasis on health security also supports immunoassay capacity for biodefense readiness, blood safety, outbreak preparedness, military medical services, and deployable diagnostics in emergency settings.

Key Country Insights for Immunoassay

The United States leads immunoassay commercialization through large reference laboratories, integrated hospital systems, established FDA pathways, and strong demand for oncology, cardiac, infectious disease, autoimmune, allergy, and endocrine testing. Canada emphasizes quality-assured diagnostics within publicly funded care, while Mexico and Brazil combine infectious disease testing needs, chronic disease screening, and expanding private laboratory networks. The United Kingdom, Germany, France, Italy, and Spain remain central to European immunoassay adoption, supported by established clinical guidelines, laboratory accreditation, universal or near-universal healthcare systems, and advanced infrastructure.

Russia maintains demand for essential diagnostics despite procurement complexity and supply chain constraints. China and India are major growth engines due to population scale, chronic disease burden, domestic manufacturing capacity, expanding hospital networks, and public health testing needs. Japan, Australia, and South Korea are advanced immunoassay markets where automation, high-quality reagents, aging demographics, precision diagnostics, and strong laboratory quality standards continue to drive adoption across centralized and decentralized testing environments.

Actionable Recommendations for Immunoassay Industry Leaders

Industry leaders should prioritize assay menus with clear clinical utility, including infectious disease, cardiac markers, thyroid function, fertility, oncology biomarkers, autoimmune testing, allergy diagnostics, inflammation markers, and therapeutic drug monitoring. Competitive advantage will come from proven sensitivity, specificity, reproducibility, lot-to-lot consistency, calibration stability, interference management, and seamless analyzer integration.

Organizations should also invest in regional regulatory readiness, IVDR transition planning, quality system maturity, cybersecurity for connected analyzers, and AI governance. Partnerships with hospitals, reference laboratories, public health agencies, academic centers, and local distributors can improve evidence generation, reimbursement access, user training, service uptime, and adoption in both mature and emerging immunoassay markets.

Research Methodology

This executive summary is based on a structured review of publicly available, authoritative sources, including regulatory agency guidance, clinical laboratory standards, World Health Organization resources, peer-reviewed literature, health system reports, public procurement information, and disclosures from established diagnostics manufacturers.

The analysis evaluates immunoassay technologies, clinical applications, regional healthcare drivers, country-level diagnostic infrastructure, regulatory conditions, laboratory automation trends, point-of-care testing adoption, and AI-enabled workflow integration. Insights were synthesized using evidence triangulation, prioritizing verifiable facts over unsupported claims and excluding speculative data that could not be linked to credible healthcare, diagnostics, regulatory, or laboratory medicine indicators.

Conclusion

Immunoassay will remain a foundational diagnostics category because it addresses high-volume clinical needs while adapting to automation, multiplexing, point-of-care testing, digital connectivity, and AI-enabled workflow support. The category's long-term relevance is reinforced by chronic disease management, infectious disease surveillance, preventive screening, blood safety, therapeutic monitoring, and precision medicine.

The next phase of leadership will depend on validated performance, regulatory discipline, accessible pricing, resilient supply chains, and intelligent workflow integration. Organizations that combine scientific reliability with scalable manufacturing, strong quality systems, clinical evidence, and evidence-based commercialization will be best positioned to meet demand across global immunoassay markets.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Immunoassay Market, by Type

  • 7.1. Qualitative Immunoassays
  • 7.2. Quantitative Immunoassays

8. Immunoassay Market, by Technology

  • 8.1. Enzyme Immunoassays
  • 8.2. Enzyme-Linked Immunosorbent Assay
  • 8.3. Fluorescent Immunoassay
  • 8.4. Lateral Flow Assay
  • 8.5. Radioimmunoassay
  • 8.6. Western Blot

9. Immunoassay Market, by Instruments

  • 9.1. Analyzers & Kits
  • 9.2. Biosensors
  • 9.3. Microfluidic Devices
  • 9.4. Microplates
  • 9.5. PCR Devices
  • 9.6. Reagents
    • 9.6.1. Antibodies
    • 9.6.2. Antigens
    • 9.6.3. Blocking Reagents
    • 9.6.4. Buffers & Standards
    • 9.6.5. Enzymes
    • 9.6.6. Substrates
  • 9.7. Software & Services

10. Immunoassay Market, by Sample Types

  • 10.1. Blood Samples
  • 10.2. Saliva Samples
  • 10.3. Tissue Samples
  • 10.4. Urine Samples

11. Immunoassay Market, by Detection Modes

  • 11.1. Chemiluminescent
  • 11.2. Colorimetric
  • 11.3. Fluorometric
  • 11.4. Radioisotopic

12. Immunoassay Market, by Application Areas

  • 12.1. Allergy
  • 12.2. Autoimmune Diseases
  • 12.3. Cardiology
  • 12.4. Endocrinology
  • 12.5. Infectious Diseases
  • 12.6. Oncology
  • 12.7. Toxicology
    • 12.7.1. Drug Screening
    • 12.7.2. Environmental Testing

13. Immunoassay Market, by End Users

  • 13.1. Contract Research Organizations
  • 13.2. Diagnostic Laboratories
  • 13.3. Hospitals & Clinics
  • 13.4. Pharmaceutical & Biotechnology Companies
  • 13.5. Research Institutions

14. Immunoassay Market, by Deployment Types

  • 14.1. Laboratory Tests
  • 14.2. Point-of-care Test

15. Immunoassay Market, by Region

  • 15.1. Asia-Pacific
  • 15.2. North America
  • 15.3. Latin America
  • 15.4. Europe
  • 15.5. Middle East
  • 15.6. Africa

16. Immunoassay Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Immunoassay Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025

19. Company Profiles

  • 19.1. Abbott Laboratories
  • 19.2. Agilent Technologies Inc.
  • 19.3. ANP Technologies, Inc.
  • 19.4. Autobio Diagnostics Co., Ltd.
  • 19.5. Becton, Dickinson and Company
  • 19.6. Bio-Rad Laboratories, Inc.
  • 19.7. Bio-Techne Corporation
  • 19.8. bioMerieux S.A.
  • 19.9. Biosurfit SA
  • 19.10. Boditech Med Inc.
  • 19.11. Danaher Corporation
  • 19.12. Diasorin S.p.A.
  • 19.13. Dynex Technologies, Inc.
  • 19.14. Epitope Diagnostics Inc.
  • 19.15. F. Hoffmann-La Roche Ltd.
  • 19.16. Fapon Biotech Inc.
  • 19.17. H.U. Group Holdings Inc.
  • 19.18. J. Mitra & Co. Pvt. Ltd.
  • 19.19. Kamiya Biomedical Company
  • 19.20. Merck KGaA
  • 19.21. MiCo BioMed, Inc.
  • 19.22. NanoEntek
  • 19.23. Nanomix, Inc.
  • 19.24. OPKO Health, Inc.
  • 19.25. Promega Corporation
  • 19.26. QIAGEN N.V.
  • 19.27. Quanterix Corporation
  • 19.28. Randox Laboratories Ltd.
  • 19.29. Shenzhen Micropoint Biotechnologies Co., Ltd.
  • 19.30. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 19.31. Siemens Healthineers AG
  • 19.32. Sysmex Corporation
  • 19.33. Thermo Fisher Scientific Inc.
  • 19.34. Tosoh Corporation
  • 19.35. WAK-Chemie Medical GmbH
  • 19.36. Zoetis Inc.
  • 19.37. Zybio Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMMUNOASSAY MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL IMMUNOASSAY MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL IMMUNOASSAY MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL IMMUNOASSAY MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL IMMUNOASSAY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNOASSAY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL IMMUNOASSAY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL IMMUNOASSAY MARKET SIZE, BY TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL IMMUNOASSAY MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL IMMUNOASSAY MARKET SIZE, BY END USERS, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL IMMUNOASSAY MARKET SIZE, BY END USERS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL IMMUNOASSAY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL IMMUNOASSAY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 29. GLOBAL IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IMMUNOASSAY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL QUALITATIVE IMMUNOASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL QUALITATIVE IMMUNOASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL QUALITATIVE IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL QUANTITATIVE IMMUNOASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL QUANTITATIVE IMMUNOASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL QUANTITATIVE IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ENZYME IMMUNOASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENZYME IMMUNOASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ENZYME IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL FLUORESCENT IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL FLUORESCENT IMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL FLUORESCENT IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LATERAL FLOW ASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LATERAL FLOW ASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LATERAL FLOW ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RADIOIMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RADIOIMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RADIOIMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL WESTERN BLOT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL WESTERN BLOT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL WESTERN BLOT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANALYZERS & KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANALYZERS & KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANALYZERS & KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOSENSORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOSENSORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOSENSORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MICROFLUIDIC DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MICROFLUIDIC DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MICROFLUIDIC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MICROPLATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MICROPLATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MICROPLATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PCR DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PCR DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PCR DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTIGENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIGENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTIGENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BLOCKING REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BLOCKING REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BLOCKING REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BUFFERS & STANDARDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BUFFERS & STANDARDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BUFFERS & STANDARDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENZYMES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ENZYMES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENZYMES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SUBSTRATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SUBSTRATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SUBSTRATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BLOOD SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BLOOD SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BLOOD SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SALIVA SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SALIVA SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SALIVA SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TISSUE SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL TISSUE SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL TISSUE SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL URINE SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL URINE SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL URINE SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CHEMILUMINESCENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CHEMILUMINESCENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CHEMILUMINESCENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL COLORIMETRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL COLORIMETRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL COLORIMETRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL FLUOROMETRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL FLUOROMETRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL FLUOROMETRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL RADIOISOTOPIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL RADIOISOTOPIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL RADIOISOTOPIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ALLERGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ALLERGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ALLERGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CARDIOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CARDIOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CARDIOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ENDOCRINOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ENDOCRINOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ENDOCRINOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL TOXICOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL TOXICOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL TOXICOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL DRUG SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL DRUG SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ENVIRONMENTAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ENVIRONMENTAL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ENVIRONMENTAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL RESEARCH INSTITUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL RESEARCH INSTITUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL RESEARCH INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL LABORATORY TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL LABORATORY TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL LABORATORY TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL POINT-OF-CARE TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL POINT-OF-CARE TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL POINT-OF-CARE TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA IMMUNOASSAY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA IMMUNOASSAY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE IMMUNOASSAY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST IMMUNOASSAY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA IMMUNOASSAY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL IMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN IMMUNOASSAY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2032 (USD MILLION)
  • TABLE 224. GCC IMMUNOASSAY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. GCC IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. GCC IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. GCC IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 228. GCC IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 229. GCC IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2032 (USD MILLION)
  • TABLE 230. GCC IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2032 (USD MILLION)
  • TABLE 231. GCC IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 232. GCC IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2032 (USD MILLION)
  • TABLE 233. GCC IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 234. GCC IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION IMMUNOASSAY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS IMMUNOASSAY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2032 (USD MILLION)
  • TABLE 257. G7 IMMUNOASSAY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 258. G7 IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. G7 IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. G7 IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 261. G7 IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 262. G7 IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2032 (USD MILLION)
  • TABLE 263. G7 IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2032 (USD MILLION)
  • TABLE 264. G7 IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 265. G7 IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2032 (USD MILLION)
  • TABLE 266. G7 IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 267. G7 IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2032 (USD MILLION)
  • TABLE 268. NATO IMMUNOASSAY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 269. NATO IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. NATO IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 271. NATO IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 272. NATO IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 273. NATO IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2032 (USD MILLION)
  • TABLE 274. NATO IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2032 (USD MILLION)
  • TABLE 275. NATO IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 276. NATO IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2032 (USD MILLION)
  • TABLE 277. NATO IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 278. NATO IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2032 (USD MILLION)
  • TABLE 279. GLOBAL IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES IMMUNOASSAY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2032 (USD MILLION)
  • TABLE 291. CANADA IMMUNOASSAY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 292. CANADA IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. CANADA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 294. CANADA IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 295. CANADA IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 296. CANADA IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2032 (USD MILLION)
  • TABLE 297. CANADA IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2032 (USD MILLION)
  • TABLE 298. CANADA IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 299. CANADA IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2032 (USD MILLION)
  • TABLE 300. CANADA IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 301. CANADA IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2032 (USD MILLION)
  • TABLE 302. MEXICO IMMUNOASSAY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 303. MEXICO IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. MEXICO IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 305. MEXICO IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 306. MEXICO IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 307. MEXICO IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2032 (USD MILLION)
  • TABLE 308. MEXICO IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2032 (USD MILLION)
  • TABLE 309. MEXICO IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 310. MEXICO IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2032 (USD MILLION)
  • TABLE 311. MEXICO IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 312. MEXICO IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2032 (USD MILLION)
  • TABLE 313. BRAZIL IMMUNOASSAY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 314. BRAZIL IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. BRAZIL IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 316. BRAZIL IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 317. BRAZIL IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 318. BRAZIL IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2032 (USD MILLION)
  • TABLE 319. BRAZIL IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2032 (USD MILLION)
  • TABLE 320. BRAZIL IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 321. BRAZIL IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2032 (USD MILLION)
  • TABLE 322. BRAZIL IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 323. BRAZIL IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED KINGDOM IMMUNOASSAY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED KINGDOM IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED KINGDOM IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED KINGDOM IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED KINGDOM IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED KINGDOM IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2032 (USD MILLION)
  • TABLE 330. UNITED KINGDOM IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2032 (USD MILLION)
  • TABLE 331. UNITED KINGDOM IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 332. UNITED KINGDOM IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2032 (USD MILLION)
  • TABLE 333. UNITED KINGDOM IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 334. UNITED KINGDOM IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2032 (USD MILLION)
  • TABLE 335. GERMANY IMMUNOASSAY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 336. GERMANY IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 337. GERMANY IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 338. GERMANY IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 339. GERMANY IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 340. GERMANY IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2032 (USD MILLION)
  • TABLE 341. GERMANY IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2032 (USD MILLION)
  • TABLE 342. GERMANY IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 343. GERMANY IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2032 (USD MILLION)
  • TABLE 344. GERMANY IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 345. GERMANY IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2032 (USD MILLION)
  • TABLE 346. FRANCE IMMUNOASSAY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 347. FRANCE IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 348. FRANCE IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 349. FRANCE IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 350. FRANCE IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 351. FRANCE IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2032 (USD MILLION)
  • TABLE 352. FRANCE IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2032 (USD MILLION)
  • TABLE 353. FRANCE IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 354. FRANCE IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2032 (USD MILLION)
  • TABLE 355. FRANCE IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 356. FRANCE IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2032 (USD MILLION)
  • TABLE 357. RUSSIA IMMUNOASSAY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 358. RUSSIA IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 359. RUSSIA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 360. RUSSIA IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 361. RUSSIA IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 362. RUSSIA IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2032 (USD MILLION)
  • TABLE 363. RUSSIA IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2032 (USD MILLION)
  • TABLE 364. RUSSIA IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 365. RUSSIA IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2032 (USD MILLION)
  • TABLE 366. RUSSIA IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 367. RUSSIA IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2032 (USD MILLION)
  • TABLE 368. ITALY IMMUNOASSAY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 369. ITALY IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 370. ITALY IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 371. ITALY IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 372. ITALY IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 373. ITALY IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2032 (USD MILLION)
  • TABLE 374. ITALY IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2032 (USD MILLION)
  • TABLE 375. ITALY IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 376. ITALY IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2032 (USD MILLION)
  • TABLE 377. ITALY IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 378. ITALY IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2032 (USD MILLION)
  • TABLE 379. SPAIN IMMUNOASSAY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 380. SPAIN IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 381. SPAIN IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 382. SPAIN IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 383. SPAIN IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 384. SPAIN IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2032 (USD MILLION)
  • TABLE 385. SPAIN IMMUNOASSAY MARKET SIZE, BY DETECTION MODES, 2018-2032 (USD MILLION)
  • TABLE 386. SPAIN IMMUNOASSAY MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 387. SPAIN IMMUNOASSAY MARKET SIZE, BY TOXICOLOGY, 2018-2032 (USD MILLION)
  • TABLE 388. SPAIN IMMUNOASSAY MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 389. SPAIN IMMUNOASSAY MARKET SIZE, BY DEPLOYMENT TYPES, 2018-2032 (USD MILLION)
  • TABLE 390. CHINA IMMUNOASSAY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 391. CHINA IMMUNOASSAY MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 392. CHINA IMMUNOASSAY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 393. CHINA IMMUNOASSAY MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 394. CHINA IMMUNOASSAY MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 395. CHINA IMMUNOASSAY MARKET SIZE, BY SAMPLE TYPES, 2018-2032 (USD MILLION)
  • TABLE 396. CHINA IMMU